Must See: Grab This Emerging Opportunity Before it Slips Away
Here is the latest financial fact sheet of PARENT.DRUGS. For more details, see the PARENT.DRUGS quarterly results and PARENT.DRUGS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 4.6 |
No. of shares | m | 29.82 |
1 Week | % | 0.0 |
1 Month | % | 0.0 |
1 Year | % | - |
52 week H/L | Rs | 5.4/3.1 |
No. of Mths Year Ending |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
5-Yr Chart Click to enlarge
|
---|
PARENT.DRUGS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 45 | 32 | 19 | 9 | 3 | |
Low | Rs | 19 | 15 | 7 | 2 | 3 | |
Sales per share (Unadj.) | Rs | 73.9 | 74.3 | 10.7 | 10.7 | 4.1 | |
Earnings per share (Unadj.) | Rs | -39.5 | -37.5 | -49.6 | -38.3 | -40.8 | |
Diluted earnings per share | Rs | -39.5 | -37.5 | -49.6 | -38.3 | -40.8 | |
Cash flow per share (Unadj.) | Rs | -31.2 | -29.4 | -26.4 | -32.4 | -35.0 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | -5.8 | -45.8 | -149.9 | -188.2 | -229.0 | |
Adj. book value per share | Rs | -5.9 | -45.8 | -149.9 | -188.3 | -229.0 | |
Shares outstanding (eoy) | m | 29.82 | 29.82 | 29.82 | 29.82 | 29.82 | |
Price / Sales ratio | x | 0.4 | 0.3 | 1.2 | 0.5 | 0.7 | |
Avg P/E ratio | x | -0.8 | -0.6 | -0.3 | -0.1 | -0.1 | |
P/CF ratio (eoy) | x | -1.0 | -0.8 | -0.5 | -0.2 | -0.1 | |
Price / Book Value ratio | x | -5.5 | -0.5 | -0.1 | 0 | 0 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 956 | 706 | 384 | 167 | 86 | |
Total wages/salary | Rs m | 208 | 219 | 199 | 192 | 145 |
PARENT.DRUGS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 2,204 | 2,216 | 320 | 319 | 122 | |
Other income | Rs m | 58 | 16 | 14 | 3 | 1 | |
Total revenues | Rs m | 2,261 | 2,232 | 334 | 321 | 122 | |
Gross profit | Rs m | -225 | -12 | -177 | -147 | -118 | |
Depreciation | Rs m | 249 | 242 | 691 | 173 | 173 | |
Interest | Rs m | 858 | 975 | 961 | 1,100 | 1,254 | |
Profit before tax | Rs m | -1,274 | -1,214 | -1,814 | -1,417 | -1,545 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | -96 | -96 | -335 | -277 | -328 | |
Profit after tax | Rs m | -1,178 | -1,118 | -1,479 | -1,141 | -1,217 | |
Gross profit margin | % | -10.2 | -0.5 | -55.2 | -46.1 | -96.8 | |
Effective tax rate | % | 7.5 | 7.9 | 18.5 | 19.5 | 21.2 | |
Net profit margin | % | -53.5 | -50.5 | -462.3 | -357.9 | -1,000.3 |
PARENT.DRUGS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 1,217 | 990 | 673 | 675 | 681 | |
Current liabilities | Rs m | 4,276 | 5,926 | 8,775 | 10,057 | 11,436 | |
Net working cap to sales | % | -138.8 | -222.7 | -2,532.2 | -2,943.5 | -8,839.3 | |
Current ratio | x | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | |
Inventory Days | Days | 19 | 19 | 130 | 139 | 375 | |
Debtors Days | Days | 103,249,798 | 6,036,309 | 0 | 0 | 0 | |
Net fixed assets | Rs m | 7,503 | 7,275 | 3,679 | 3,513 | 3,343 | |
Share capital | Rs m | 298 | 298 | 298 | 298 | 298 | |
"Free" reserves | Rs m | -473 | -1,663 | -4,767 | -5,911 | -7,127 | |
Net worth | Rs m | -174 | -1,364 | -4,469 | -5,613 | -6,829 | |
Long term debt | Rs m | 5,032 | 4,338 | 1,097 | 1,072 | 1,072 | |
Total assets | Rs m | 8,720 | 8,265 | 4,352 | 4,187 | 4,024 | |
Interest coverage | x | -0.5 | -0.2 | -0.9 | -0.3 | -0.2 | |
Debt to equity ratio | x | -28.8 | -3.2 | -0.2 | -0.2 | -0.2 | |
Sales to assets ratio | x | 0.3 | 0.3 | 0.1 | 0.1 | 0 | |
Return on assets | % | -3.7 | -1.7 | -11.9 | -1.0 | 0.9 | |
Return on equity | % | 675.5 | 81.9 | 33.1 | 20.3 | 17.8 | |
Return on capital | % | -8.6 | -8.0 | 25.3 | 7.0 | 5.0 | |
Exports to sales | % | 3.0 | 1.9 | 0.8 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 67 | 42 | 3 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 67 | 42 | 3 | 0 | 0 | |
Fx outflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Net fx | Rs m | 67 | 42 | 3 | 0 | 0 |
PARENT.DRUGS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 1,344 | 1,670 | 4,770 | 1,124 | 1,253 | |
From Investments | Rs m | -5 | -6 | 966 | 1 | 1 | |
From Financial Activity | Rs m | -1,344 | -1,666 | -5,736 | -1,124 | -1,254 | |
Net Cashflow | Rs m | -5 | -3 | 0 | 0 | -1 |
Share Holding
Shareholding as on Mar 2022
|
Company Information
|
CHM: Manohar Lal Gupta | COMP SEC: Pooja Choukse | YEAR OF INC: 1983 | BSE CODE: 524689 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare PARENT.DRUGS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.